In short
Clinical trials are investigating LY3537031 in adults with alcohol use disorder and uncontrolled moderate to severe asthma. These studies aim to check whether the treatment works better than placebo and to measure safety, response, and longer-term effects in different patient groups.
Key points
- Clinical trials of LY3537031 are being done in adults with alcohol use disorder and in adults with uncontrolled moderate to severe asthma. Two studies are Phase 3 trials in alcohol use disorder, and one is a Phase 2 trial in asthma. The alcohol studies look at alcohol-related behaviors, reduction in alcohol consumption, and whether benefits can be maintained over time. The asthma study measures whether the treatment lowers the rate of severe asthma flare-ups over 52 weeks. All three studies are authorised and use placebo comparison to test how well LY3537031 performs.
Clinical trials overview
Current studies of LY3537031 are testing it in two different conditions: alcohol use disorder and uncontrolled moderate to severe asthma. These are interventional studies, which means researchers give a study treatment and compare results with placebo.
All three trials are listed as Authorised. Two studies are in Phase 3, and one study is in Phase 2.
Alcohol use disorder studies
Two Phase 3 trials are studying LY3537031 in people with alcohol use disorder, including one study in participants with moderate-to-severe alcohol use disorder. The planned enrollment is 949 participants in one study and 1,090 participants in the other.
The main goal in both alcohol studies is to show that at least one dose level is better than placebo for at least one of the dual primary endpoints. In simple terms, this means the researchers want to see whether LY3537031 helps people do better than placebo on the main results the study is designed to measure.
These studies also include a second period for responders, meaning people who improved in Period 1. In Period 2, the trial checks whether LY3537031 can help maintain a general reduction in alcohol consumption over time.
One alcohol study lists the primary outcome as behaviors associated with alcohol use disorder, measured by the Timeline Followback Method (TLFB). TLFB is a structured way to track drinking behavior over a set period.
Asthma study
One Phase 2 trial is studying LY3537031 in adult participants with uncontrolled moderate to severe asthma. The study plans to enroll 538 participants.
The main purpose of this trial is to compare LY3537031 with placebo and see whether it reduces severe asthma exacerbations. An asthma exacerbation is a worsening of asthma symptoms, often called a flare-up or attack.
The primary outcome is the annualized asthma exacerbation rate over 52 weeks of treatment, measured from baseline to Week 52. This means the study counts how often severe asthma flare-ups happen during the treatment period.
Main endpoints and what they mean
A primary endpoint is the main result a clinical trial uses to decide whether the treatment is working. In the alcohol studies, the endpoints focus on alcohol-related behavior and reduced alcohol consumption.
In the asthma study, the main endpoint is the rate of severe flare-ups during one year of treatment. This helps researchers understand whether the study treatment can lower the number of asthma worsening events over time.
Who may take part
The alcohol use disorder trials are for participants with alcohol use disorder, and one of them specifically names moderate-to-severe alcohol use disorder. The asthma trial is for adult participants with uncontrolled moderate to severe asthma.
Each study has its own entry rules, but the trial records show the main target groups clearly. The studies are designed for people who have the condition being tested, not for the general population.
Trial design and study status
All three studies are interventional and compare LY3537031 with placebo. The alcohol studies use a multi-period design, with an early period to test response and a later period to see whether benefits last in responders.
The asthma study follows participants for 52 weeks, which gives researchers a longer view of asthma control during treatment. All studies are currently marked as authorised, which means they have been approved to move forward in the trial process.